Quick Evidence Summary
| Evidence type | Current status |
|---|---|
| Human trials of IGF-1 LR3 itself | None published |
| Epidemiological data on native IGF-1 | Substantial - large prospective cohort studies (EPIC-Heidelberg) |
| Cancer-risk signal | From native IGF-1 levels, not IGF-1 LR3 trials specifically |
| Mechanistic relevance of that data | Direct - same receptor and PI3K/Akt/mTOR pathway |
| Regulatory status | Not FDA-approved; multiple FDA warning letters issued to marketers |
What IGF-1 LR3 Is
IGF-1 LR3 is a long-acting analogue of insulin-like growth factor 1 (IGF-1), engineered with an extended amino acid sequence that reduces its binding to IGF-1 binding proteins. That modification amplifies and prolongs its biological activity at the IGF-1 receptor compared to native IGF-1, which is the basis for its research-community interest in muscle hypertrophy and nutrient uptake. It was originally developed and characterized as a laboratory research tool for cell-culture and animal studies, not as a drug candidate for humans.
Why There's No Human Trial Data, and Where the Safety Signal Actually Comes From
There are no published human clinical trials of IGF-1 LR3 specifically. It was never put through a drug-development pipeline, so there's no pivotal trial, no dose-ranging study, and no controlled efficacy data on the compound itself.
The safety and cancer-risk concerns commonly cited for IGF-1 LR3 come from a different, legitimate body of evidence: large prospective cohort research on naturally circulating IGF-1 in humans. The EPIC-Heidelberg study found that higher circulating IGF-1 was associated with increased risk of breast cancer (relative risk 1.25) and prostate cancer (relative risk 1.31), consistent with IGF-1's role in promoting cell proliferation and inhibiting apoptosis via the PI3K/Akt/mTOR pathway.
Why this matters: IGF-1 LR3 is engineered specifically to resist normal IGF-1 binding proteins, which amplifies and prolongs activity at that same receptor and pathway. The epidemiological cancer-risk signal is mechanistically relevant even though it wasn't measured using IGF-1 LR3 itself, which is a different kind of evidence than a trial of the compound, not a weaker or irrelevant one.
Evidence Gaps and Regulatory Status
IGF-1 LR3 is not FDA-approved for human use, has no USP or NF drug substance monograph, and does not appear on the FDA's 503A bulk drug substance list, meaning it cannot legally be compounded for human use by any registered pharmacy. Products sold as IGF-1 LR3 are marketed strictly as research chemicals for laboratory research use only. Between 2017 and 2022, the FDA issued numerous warning letters to companies marketing IGF-1 LR3 in bodybuilding, anti-aging, and performance-enhancement products, citing distribution of an unapproved new drug. Chronic excess IGF-1 signaling is also linked to acromegaly-like tissue changes, including jaw, hand, and cardiac enlargement, with long-term overexposure - a concern grounded in known IGF-1 physiology rather than speculation.
Bloodwork to Track
Given the mechanism, fasting blood glucose is a relevant marker to track for hypoglycemia risk, and IGF-1 level itself is a reasonable thing to monitor given the epidemiological signal described above. See the peptide bloodwork guide for what a baseline panel typically includes.
Related Reading
For research dosing conventions and the full safety breakdown, see the IGF-1 LR3 reference page. BioStackIQ's Rate My Stack and Build Protocol can help you think through where a compound like this fits into a broader stack, with this evidence picture in mind.